The European Medicines Agency has at last published its much-awaited draft guidance on how advanced therapy medicinal product (ATMP) sponsors should design their development programs using a risk-based approach.
The draft guidance, which is out for consultation until Aug. 1, explains how developers of gene, cell-based and tissue-engineered products...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?